213 related articles for article (PubMed ID: 38306168)
1. JAK/STAT defects and immune dysregulation, and guiding therapeutic choices.
Chaimowitz NS; Smith MR; Forbes Satter LR
Immunol Rev; 2024 Mar; 322(1):311-328. PubMed ID: 38306168
[TBL] [Abstract][Full Text] [Related]
2. Emerging Place of JAK Inhibitors in the Treatment of Inborn Errors of Immunity.
Hadjadj J; Frémond ML; Neven B
Front Immunol; 2021; 12():717388. PubMed ID: 34603291
[TBL] [Abstract][Full Text] [Related]
3. Small molecule drug discovery targeting the JAK-STAT pathway.
Lv Y; Mi P; Babon JJ; Fan G; Qi J; Cao L; Lang J; Zhang J; Wang F; Kobe B
Pharmacol Res; 2024 Jun; 204():107217. PubMed ID: 38777110
[TBL] [Abstract][Full Text] [Related]
4. JAK inhibitor treatment for inborn errors of JAK/STAT signaling: An ESID/EBMT-IEWP retrospective study.
Fischer M; Olbrich P; Hadjadj J; Aumann V; Bakhtiar S; Barlogis V; von Bismarck P; Bloomfield M; Booth C; Buddingh EP; Cagdas D; Castelle M; Chan AY; Chandrakasan S; Chetty K; Cougoul P; Crickx E; Dara J; Deyà-Martínez A; Farmand S; Formankova R; Gennery AR; Gonzalez-Granado LI; Hagin D; Hanitsch LG; Hanzlikovà J; Hauck F; Ivorra-Cortés J; Kisand K; Kiykim A; Körholz J; Leahy TR; van Montfrans J; Nademi Z; Nelken B; Parikh S; Plado S; Ramakers J; Redlich A; Rieux-Laucat F; Rivière JG; Rodina Y; Júnior PR; Salou S; Schuetz C; Shcherbina A; Slatter MA; Touzot F; Unal E; Lankester AC; Burns S; Seppänen MRJ; Neth O; Albert MH; Ehl S; Neven B; Speckmann C
J Allergy Clin Immunol; 2024 Jan; 153(1):275-286.e18. PubMed ID: 37935260
[TBL] [Abstract][Full Text] [Related]
5. Targeting JAK/STAT signaling pathways in treatment of inflammatory bowel disease.
Wang L; Hu Y; Song B; Xiong Y; Wang J; Chen D
Inflamm Res; 2021 Jul; 70(7):753-764. PubMed ID: 34212215
[TBL] [Abstract][Full Text] [Related]
6. Molecular dissection of Janus kinases as drug targets for inflammatory diseases.
Kwon S
Front Immunol; 2022; 13():1075192. PubMed ID: 36569926
[TBL] [Abstract][Full Text] [Related]
7. JAK-STAT signaling in human disease: From genetic syndromes to clinical inhibition.
Luo Y; Alexander M; Gadina M; O'Shea JJ; Meylan F; Schwartz DM
J Allergy Clin Immunol; 2021 Oct; 148(4):911-925. PubMed ID: 34625141
[TBL] [Abstract][Full Text] [Related]
8. Dual-target Janus kinase (JAK) inhibitors: Comprehensive review on the JAK-based strategies for treating solid or hematological malignancies and immune-related diseases.
Shen P; Wang Y; Jia X; Xu P; Qin L; Feng X; Li Z; Qiu Z
Eur J Med Chem; 2022 Sep; 239():114551. PubMed ID: 35749986
[TBL] [Abstract][Full Text] [Related]
9. The role of JAK-STAT signaling pathway and its regulators in the fate of T helper cells.
Seif F; Khoshmirsafa M; Aazami H; Mohsenzadegan M; Sedighi G; Bahar M
Cell Commun Signal; 2017 Jun; 15(1):23. PubMed ID: 28637459
[TBL] [Abstract][Full Text] [Related]
10. The role of JAK/STAT signaling pathway and its inhibitors in diseases.
Xin P; Xu X; Deng C; Liu S; Wang Y; Zhou X; Ma H; Wei D; Sun S
Int Immunopharmacol; 2020 Mar; 80():106210. PubMed ID: 31972425
[TBL] [Abstract][Full Text] [Related]
11. JAK-STAT pathway inhibitors in dermatology.
Miot HA; Criado PR; de Castro CCS; Ianhez M; Talhari C; Ramos PM
An Bras Dermatol; 2023; 98(5):656-677. PubMed ID: 37230920
[TBL] [Abstract][Full Text] [Related]
12. JAK-STAT Pathway: A Novel Target to Tackle Viral Infections.
Ezeonwumelu IJ; Garcia-Vidal E; Ballana E
Viruses; 2021 Nov; 13(12):. PubMed ID: 34960648
[TBL] [Abstract][Full Text] [Related]
13. Evolving cognition of the JAK-STAT signaling pathway: autoimmune disorders and cancer.
Xue C; Yao Q; Gu X; Shi Q; Yuan X; Chu Q; Bao Z; Lu J; Li L
Signal Transduct Target Ther; 2023 May; 8(1):204. PubMed ID: 37208335
[TBL] [Abstract][Full Text] [Related]
14. Janus kinase inhibitors in autoimmune bullous diseases.
Huang D; Zhang Y; Kong L; Lu J; Shi Y
Front Immunol; 2023; 14():1220887. PubMed ID: 37492565
[TBL] [Abstract][Full Text] [Related]
15. Translational and clinical advances in JAK-STAT biology: The present and future of jakinibs.
Gadina M; Johnson C; Schwartz D; Bonelli M; Hasni S; Kanno Y; Changelian P; Laurence A; O'Shea JJ
J Leukoc Biol; 2018 Sep; 104(3):499-514. PubMed ID: 29999544
[TBL] [Abstract][Full Text] [Related]
16. Targeting the JAK-STAT pathway in autoimmune diseases and cancers: A focus on molecular mechanisms and therapeutic potential.
Tzeng HT; Chyuan IT; Lai JH
Biochem Pharmacol; 2021 Nov; 193():114760. PubMed ID: 34492272
[TBL] [Abstract][Full Text] [Related]
17. Working and safety profiles of JAK/STAT signaling inhibitors. Are these small molecules also smart?
Favoino E; Prete M; Catacchio G; Ruscitti P; Navarini L; Giacomelli R; Perosa F
Autoimmun Rev; 2021 Mar; 20(3):102750. PubMed ID: 33482338
[TBL] [Abstract][Full Text] [Related]
18. JAK-STAT signaling pathway in the pathogenesis of atopic dermatitis: An updated review.
Huang IH; Chung WH; Wu PC; Chen CB
Front Immunol; 2022; 13():1068260. PubMed ID: 36569854
[TBL] [Abstract][Full Text] [Related]
19. Why Do We Need JAK Inhibitors in Systemic Lupus Erythematosus?
Richter P; Cardoneanu A; Burlui AM; Macovei LA; Bratoiu I; Buliga-Finis ON; Rezus E
Int J Mol Sci; 2022 Oct; 23(19):. PubMed ID: 36233087
[TBL] [Abstract][Full Text] [Related]
20. An overview of JAK/STAT pathways and JAK inhibition in alopecia areata.
Lensing M; Jabbari A
Front Immunol; 2022; 13():955035. PubMed ID: 36110853
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]